Lunit announces new members to its advisory board
Lunit, a medical AI software company, today announced new members of its advisory board, world-renowned medical experts, Drs. Eliot Siegel, Linda Moy, and Khan Siddiqui.
“We welcome Drs. Siegel, Moy, and Siddiqui as our advisors,” said Brandon Suh, CEO of Lunit. “We are proud to have such distinguished and respected experts in radiology as our advisors in our journey in advancing medical intelligence to the next level. We are thrilled to be working with them, and with their help, we believe we can better achieve our goal to deliver state-of-the-art AI solutions that properly address unmet clinical needs.”
Dr. Eliot Siegel, FACR, FSIIM, is known as a visionary in radiology and one of the early pioneers of the Picture Archiving and Communication Systems (PACS), is Professor and Vice Chairman of Research Information Systems at the University of Maryland, Adjunct Professor of Computer Science and Biomedical Engineering at University of Maryland, and is Chief of Radiology and Nuclear Medicine for the Veterans Affairs Maryland Healthcare System, Baltimore, MD. Under his guidance, VA Maryland Healthcare System became the first filmless healthcare enterprise in the world. He has served various leadership positions in academic societies including SPIE, SIIM, ACR, the National Cancer Institute, and the RSNA and currently serves as co-chair of the Conference on Machine Intelligence in Medical Imaging. He has written over 300 articles and book chapters about PACS and digital imaging and has made more than 1,000 presentations throughout the world on a broad range of topics involving the use of computers in medicine.
“Deep Learning, commonly referred to as AI, will have a profound impact on Diagnostic Imaging in the next several years and will become an indispensable and ubiquitous tool in routine clinical practice," said Dr. Siegel. "Innovations will come partly from large and well-established healthcare and imaging vendors, but particularly from nimble and creative start-ups and other smaller companies with core expertise in machine learning or niche clinical applications. The sophistication, efficacy, and safety of these vary considerably, especially in these early times of AI implementation. I have been particularly impressed with Lunit’s academic/research pedigree including numerous publications that have advanced the science of machine learning in imaging, their impressive success in Imagenet, Camelyon and other computer vision competitions, and their clinical leadership including 6 board certified medical directors and 15 additional radiologists/pathologists. This combination of pushing the research envelope and solid clinical input and leadership serves as a model for the evolution of AI vendors in medical imaging.”
Dr. Linda Moy, a key opinion leader in breast imaging, is a professor at NYU School of Medicine. She holds a joint appointment at the NYU Langone Medical Center and at the NYU Center for Advanced Imaging Innovation and Research. Her career as a clinician and researcher focuses on diagnostic oncologic imaging, with an emphasis on the detection of breast cancer.
Her research team has been awarded major research grants from the National Institute of Health and Department of Defense. She has authored or co-authored more than 140 original research articles, reviews, and editorial articles. She is the editor of two textbooks on breast MRI. She has made more than 100 major presentations at international events. She is the Chair of the Radiological Society of North America’s Scientific Program Committee on Breast Imaging. She also serves as a Deputy Editor for Breast Imaging at Radiology. She is the chair of the American College of Radiology (ACR) Joint Committee on Breast Imaging for the Appropriateness Criteria and chair of the ACR Practice Parameters and Technical Standards. In addition, she holds leadership positions in the International Society for Magnetic Resonance in Medicine, American Roentgen Ray Society and the Society of Breast Imaging.
“Lunit has developed innovative solutions that address the limitations of screening Mammography,” said Dr. Moy. “Although their advanced medical image analytics will improve diagnostic accuracy, I’m particularly excited about their development of novel imaging biomarkers that will improve the quality of care for our patients.”
Serial Entrepreneur, Founder and Chief Medical/Chief Technology Officer of higi, a medical technology company that makes self-service health stations, Dr. Khan Siddiqui brings over 22 years of experience as a practicing clinician and technology professional. A visiting Associate Professor at the Department of Radiology at John Hopkins University School of Medicine, former Co-Director at the Center for Biomedical & Imaging Informatics, Johns Hopkins University. Prior to founding higi in 2012, Dr. Siddiqui was a Physician Executive and Principal Program Manager at Microsoft. Dr. Siddiqui has published dozens of peer-reviewed publications and holds 12 patents for technology in areas of deep learning, AI, image processing, data visualization, as well as securing patient information handling and health records.
“Radiologists play an immense role in improving patient outcomes via early disease detection,” said Dr. Siddiqui. “Great advancements in artificial intelligence-based disease detection solutions by Lunit will lead to earlier and faster diagnosis, thereby improving radiologists’ accuracy and productivity. I am excited to join the advisory board to help guide product development and address pressing clinical needs of early disease detection with AI enabled tools.”
Drs. Siegel, Moy, and Siddiqui will join Drs. Jihoon Jeong and Kyunghyun Cho in providing expert insight at Lunit’s advisory board.
“At this stage, when we are shifting our gears from research and development to global commercialization of our products, we feel honored to have these internationally acclaimed experts on our board, who can help us pave our path in the world of medical AI,” said Suh. “We are truly fortunate to have them by our side in this adventure and together, I am confident that we will be successful in creating a remarkable impact on the medical society worldwide.”